Dendreon Earnings Preview: Get Ahead of the Analysts

Dendreon (NASDAQ:DNDN) will report earnings before markets open on Thursday, May 9th. Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. The Company combines knowledge in immunology and antigen engineering with proprietary cell separation technologies to develop therapeutic vaccines that induce cell-mediated immunity, the body’s key defense against cancer.

Here is your Cheat Sheet to Dendreon Earnings:

Earnings Expectations: Analysts expect earnings of $-0.48 per share on revenues of $80.15 million.

Analyst Trends:

Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.38 to a loss $0.42. For the current year, the average estimate is a loss of $1.51, which is worse than the estimate ninety days ago.

Earnings Trends:

Here’s how Dendreon has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 0.11 0.10 48.06 341.61 325.53
Diluted EPS ($) -0.79 -2.04 -3.18 -2.31 -2.65

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012
Revenue ($) in millions 202.14 82.07 79.99 77.97 85.49
Diluted EPS ($) 0.2595 -0.70 -0.65 -1.04 -0.2584

Past Performance:
Dendreon has missed analyst estimates 3 times in the past four quarters. Shareholders could expect a bust if the company misses estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)

More Articles About:   , , , ,